NeuroVive releases video presentation

NeuroVive is currently holding a rights issue. Today, it released a video presentation which is available on the websites of both NeuroVive and AktieTorget. In this video, NeuroVive is presented by the company’s MD and CSO, Eskil Elmér.

In this presentation, NeuroVive’s MD and CSO Eskil Elmér, who is also a physician and associate professor of experimental neurology, talks about NeuroVive and its activities. The video presentation is available on both the company’s website (www.neurovive.se) and that of AktieTorget (www.aktietorget.se).

NeuroVive and its current rights issue

NeuroVive is engaged in research and development into nerve-cell-protecting drugs for treating traumatic brain damage and other neurological damage for which there is currently no effective treatment. NeuroVive is holding a rights issue prior to its listing on AktieTorget.

Subscription period: 11 August – 3 September 2008
Subscription price SEK 7.60 per share

Smallcap analysis

NeuroVive’s website also includes an analysis by Smallcap.

For more information contact:

Eskil Elmér
MD and CSO, Neurovive Pharmaceutical AB (publ)

Telefon: + 46 (0)46-288 01 10
eskil(punkt)elmer(snabel-a)neurovive(punkt)se

NeuroVive is involved in research and development into cyclosporine-based drugs, also known as cyclophilin-D inhibitors. The company’s first product, NeuroSTAT®, is now ready for clinical trials in humans. NeuroVive is also involved in advanced research and development into new potential drugs that could protect nerve cells. The company holds broad patent rights to a family of drugs known as cyclosporines. NeuroVive intends to license products to major pharmaceutical companies for registration and marketing.